Investing.com - Corcept (NASDAQ: CORT) reported third quarter EPS of $0.28, $0.06 better than the analyst estimate of $0.22. Revenue for the quarter came in at $123.6M versus the...
Investing.com - Corcept (NASDAQ: CORT) reported second quarter EPS of $0.25, $0.10 better than the analyst estimate of $0.15. Revenue for the quarter came in at $117.7M versus the...
Investing.com - Corcept (NASDAQ: CORT) reported first quarter EPS of $0.14, $0.05 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $105.7M versus the...
By Davit KirakosyanInvesting.com -- Here are 5 biggest share buyback announcements from the past week you may have missed on InvestingPro. Start your free 7-day trial to get this...
Corcept Therapeutics (NASDAQ:CORT) reported Q4 EPS of $0.14, $0.10 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $103.1 million versus the...
Investing.com - Corcept (NASDAQ: CORT) reported fourth quarter EPS of $0.14, $0.10 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $103.1M versus the...
Corcept Therapeutics (NASDAQ:CORT) reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $103.4 million versus the...